top of page
All Posts
Jorna Therapeutics and ONO Pharmaceutical Announce Strategic Partnership to Accelerate Innovation in RNA Editing
Cambridge, Massachusetts, April 21, 2025 – Jorna Therapeutics, a biotechnology company based in Cambridge, MA (“Jorna”), and Ono...
Apr 212 min read
540 views
Jorna welcomes Dr. Yong Dai to join as its President
I am thrilled to announce that Yong Dai has joined Jorna Therapeutics as our new President! Yong brings an unparalleled track record...
Jan 141 min read
84 views
Quantum Sky wins the Inaugural Diamond Ticket by LabCentral and Astellas
Please follow this link to read the full report. Full Text below: $500,000 credit for private biomanufacturing lab space at LabCentral...
Oct 29, 20244 min read
66 views
The Sky's the limit for novel proteins
SkyEngine's introduction appeared on Nature's special issue in Biopharma Dealmakers. Please use this link to access the details. Full...
Sep 24, 20244 min read
58 views
SkyEngine works with Sherlock Biosciences in Discovery of Novel CRISPR-Cas Enzymes, Enabling Simple Multiplex Diagnostic Solutions
Sherlock Biosciences, in collaboration with Rosetta Biosciences, has discovered novel thermostable CRISPR-associated (Cas) enzymes that enhance the capabilities of their SHERLOCK™ platform. These enzymes enable real-time, multiplexed detection of multiple RNA and/or DNA targets in a single test, advancing point-of-care diagnostics. The SHERLOCK technology, licensed from the Broad Institute, powers the first FDA-authorized CRISPR-based diagnostic, the Sherlock™ CRISPR SARS-CoV
Dec 7, 20202 min read
56 views
bottom of page